Literature DB >> 30840159

Intensive multidisciplinary management in critical care patients affected by severe necrotizing soft tissue infections: a cooperative method to improve the efficacy of treatment.

Milo Gatti1, Laura Elisa Gasparini2, Matteo Laratta3, Anna Sigurtà2, Anna Rossi2, Paolo Brioschi2, Osvaldo Chiara4, Chiara Vismara5, Francesco Scaglione6, Sergio Arlati7.   

Abstract

To illustrate the effectiveness of our intensive multidisciplinary management (IMM) in the treatment of severely ill patients with necrotizing soft tissue infections (NSTIs). A retrospective observational study was conducted in a general ICU. Thirty-two consecutive patients undergoing IMM were carefully compared with 30 consecutive patients receiving a standard management (SM). IMM combined intensive care management, early surgical debridement followed by daily inspection of surgical wounds, close microbiological surveillance, and targeted high-dose antibiotics. IMM was associated with the better decrease of daily SOFA score (p = 0.04). Also, IMM caused + 12% increase in the overall number of surgical procedures (p = 0.022) and a higher number of tissue biopsies/per day (median 0.63 versus 0.32; p = 0.025), leading to a more targeted antimicrobial changes (89.6% vs 51.6%; p < 0.00001). High-dose daptomycin (75% vs 36.7%; p = 0.002) and extended/continuous infusion of beta-lactams (75% vs 43.3%; p = 0.011) were more frequently utilized. A specific efficiency score correlated with the decrease of SOFA score (efficacy) in IMM patients only (p = 0.027). Finally, IMM was associated with a significant lower ICU mortality rate (15.6% vs 40%; p = 0.032). IMM was more effective than SM as it allowed the earlier control of infection and the faster reduction of multiple organ-dysfunction.

Entities:  

Keywords:  Antibiotic de-escalation; Intensive care unit; Intensive multidisciplinary management; Severe necrotizing soft tissue infections; Targeted antimicrobial therapy

Mesh:

Substances:

Year:  2019        PMID: 30840159     DOI: 10.1007/s10096-019-03521-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

Review 1.  Mechanisms of action of newer antibiotics for Gram-positive pathogens.

Authors:  Robert Ew Hancock
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

2.  Influence of surgical treatment timing on mortality from necrotizing soft tissue infections requiring intensive care management.

Authors:  Alexandre Boyer; Frederic Vargas; Fanny Coste; Elodie Saubusse; Yves Castaing; Georges Gbikpi-Benissan; Gilles Hilbert; Didier Gruson
Journal:  Intensive Care Med       Date:  2008-12-20       Impact factor: 17.440

3.  The exposure treatment of burns.

Authors:  A B WALLACE
Journal:  Lancet       Date:  1951-03-03       Impact factor: 79.321

Review 4.  Necrotizing soft-tissue infection: diagnosis and management.

Authors:  Daniel A Anaya; E Patchen Dellinger
Journal:  Clin Infect Dis       Date:  2007-01-22       Impact factor: 9.079

5.  Predictors of mortality and limb loss in necrotizing soft tissue infections.

Authors:  Daniel A Anaya; Kerry McMahon; Avery B Nathens; Stephen R Sullivan; Hugh Foy; Eileen Bulger
Journal:  Arch Surg       Date:  2005-02

Review 6.  Antibiotic dosing in multiple organ dysfunction syndrome.

Authors:  Marta Ulldemolins; Jason A Roberts; Jeffrey Lipman; Jordi Rello
Journal:  Chest       Date:  2011-05       Impact factor: 9.410

Review 7.  Pharmacokinetic issues for antibiotics in the critically ill patient.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2009-03       Impact factor: 7.598

8.  The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections.

Authors:  Chin-Ho Wong; Lay-Wai Khin; Kien-Seng Heng; Kok-Chai Tan; Cheng-Ooi Low
Journal:  Crit Care Med       Date:  2004-07       Impact factor: 7.598

9.  Cellulitis incidence in a defined population.

Authors:  S M Ellis Simonsen; E R van Orman; B E Hatch; S S Jones; L H Gren; K T Hegmann; J L Lyon
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

10.  Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality.

Authors:  Chin-Ho Wong; Haw-Chong Chang; Shanker Pasupathy; Lay-Wai Khin; Jee-Lim Tan; Cheng-Ooi Low
Journal:  J Bone Joint Surg Am       Date:  2003-08       Impact factor: 5.284

View more
  4 in total

1.  Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients.

Authors:  Milo Gatti; Pier Giorgio Cojutti; Michele Bartoletti; Tommaso Tonetti; Amedeo Bianchini; Stefania Ramirez; Giacinto Pizzilli; Simone Ambretti; Maddalena Giannella; Rita Mancini; Antonio Siniscalchi; Pierluigi Viale; Federico Pea
Journal:  Crit Care       Date:  2022-06-14       Impact factor: 19.334

2.  Impact of a multidisciplinary care bundle for necrotizing skin and soft tissue infections: a retrospective cohort study.

Authors:  Tomas Urbina; Camille Hua; Emilie Sbidian; Romain Bosc; Françoise Tomberli; Raphael Lepeule; Jean-Winoc Decousser; Armand Mekontso Dessap; Olivier Chosidow; Nicolas de Prost
Journal:  Ann Intensive Care       Date:  2019-10-24       Impact factor: 6.925

3.  Incidence and mortality of necrotizing fasciitis in The Netherlands: the impact of group A Streptococcus.

Authors:  Femke Nawijn; Brechje de Gier; Diederik A H Brandwagt; Rolf H H Groenwold; Jort Keizer; Falco Hietbrink
Journal:  BMC Infect Dis       Date:  2021-12-06       Impact factor: 3.090

4.  Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice.

Authors:  Milo Gatti; Simona Barnini; Fabio Guarracino; Eva Maria Parisio; Michele Spinicci; Bruno Viaggi; Sara D'Arienzo; Silvia Forni; Angelo Galano; Fabrizio Gemmi
Journal:  Antibiotics (Basel)       Date:  2022-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.